Systemic therapy options in BRCA mutation-associated breast cancer

Soley Bayraktar, Stefan Glück

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

BRCA mutation-associated breast cancers are characterized by deficient homologous recombination of DNA, and 80 % of BRCA1-associated breast cancers display the basal-like molecular subtype. Traditionally, BRCA carriers have received conventional systemic chemotherapy based on their baseline tumor characteristics, and it is generally accepted that after the appropriate treatment the prognosis of a mutation carrier is equivalent to that of a patient with sporadic breast cancer. However, with the growing understanding of the functions of BRCA1/2 proteins in homologous DNA repair, it is recognized that BRCA-associated breast cancer tumors may have distinct biochemical characteristics and thus require tailored treatment strategies. Tumors arising in patients with BRCA mutations were shown to be particularly sensitive to platinum compounds or inhibitors of poly(ADP-ribose) polymerase. In addition, BRCA1-mutation carriers seem to benefit from anthracycline-taxane-containing regimens as much as sporadic triple-negative breast cancers do. In this article, we review the functions of the BRCA1 and BRCA2 genes, and their differential chemosensitivity in both the preclinical and clinical settings. The optimal chemotherapy regimen for this subset of patients still remains to be determined.

Original languageEnglish
Pages (from-to)355-366
Number of pages12
JournalBreast Cancer Research and Treatment
Volume135
Issue number2
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Breast Neoplasms
Mutation
BRCA1 Protein
BRCA2 Gene
Triple Negative Breast Neoplasms
Platinum Compounds
BRCA1 Gene
Therapeutics
Drug Therapy
Anthracyclines
Homologous Recombination
DNA Repair
Neoplasms
DNA

Keywords

  • BRCA 1
  • BRCA 2
  • Chemotherapy
  • Cisplatin
  • PARP inhibitors
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Systemic therapy options in BRCA mutation-associated breast cancer. / Bayraktar, Soley; Glück, Stefan.

In: Breast Cancer Research and Treatment, Vol. 135, No. 2, 01.09.2012, p. 355-366.

Research output: Contribution to journalArticle

Bayraktar, Soley ; Glück, Stefan. / Systemic therapy options in BRCA mutation-associated breast cancer. In: Breast Cancer Research and Treatment. 2012 ; Vol. 135, No. 2. pp. 355-366.
@article{b2b21cbb89a4480aa6d87cfee7c5a402,
title = "Systemic therapy options in BRCA mutation-associated breast cancer",
abstract = "BRCA mutation-associated breast cancers are characterized by deficient homologous recombination of DNA, and 80 {\%} of BRCA1-associated breast cancers display the basal-like molecular subtype. Traditionally, BRCA carriers have received conventional systemic chemotherapy based on their baseline tumor characteristics, and it is generally accepted that after the appropriate treatment the prognosis of a mutation carrier is equivalent to that of a patient with sporadic breast cancer. However, with the growing understanding of the functions of BRCA1/2 proteins in homologous DNA repair, it is recognized that BRCA-associated breast cancer tumors may have distinct biochemical characteristics and thus require tailored treatment strategies. Tumors arising in patients with BRCA mutations were shown to be particularly sensitive to platinum compounds or inhibitors of poly(ADP-ribose) polymerase. In addition, BRCA1-mutation carriers seem to benefit from anthracycline-taxane-containing regimens as much as sporadic triple-negative breast cancers do. In this article, we review the functions of the BRCA1 and BRCA2 genes, and their differential chemosensitivity in both the preclinical and clinical settings. The optimal chemotherapy regimen for this subset of patients still remains to be determined.",
keywords = "BRCA 1, BRCA 2, Chemotherapy, Cisplatin, PARP inhibitors, Triple-negative breast cancer",
author = "Soley Bayraktar and Stefan Gl{\"u}ck",
year = "2012",
month = "9",
day = "1",
doi = "10.1007/s10549-012-2158-6",
language = "English",
volume = "135",
pages = "355--366",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Systemic therapy options in BRCA mutation-associated breast cancer

AU - Bayraktar, Soley

AU - Glück, Stefan

PY - 2012/9/1

Y1 - 2012/9/1

N2 - BRCA mutation-associated breast cancers are characterized by deficient homologous recombination of DNA, and 80 % of BRCA1-associated breast cancers display the basal-like molecular subtype. Traditionally, BRCA carriers have received conventional systemic chemotherapy based on their baseline tumor characteristics, and it is generally accepted that after the appropriate treatment the prognosis of a mutation carrier is equivalent to that of a patient with sporadic breast cancer. However, with the growing understanding of the functions of BRCA1/2 proteins in homologous DNA repair, it is recognized that BRCA-associated breast cancer tumors may have distinct biochemical characteristics and thus require tailored treatment strategies. Tumors arising in patients with BRCA mutations were shown to be particularly sensitive to platinum compounds or inhibitors of poly(ADP-ribose) polymerase. In addition, BRCA1-mutation carriers seem to benefit from anthracycline-taxane-containing regimens as much as sporadic triple-negative breast cancers do. In this article, we review the functions of the BRCA1 and BRCA2 genes, and their differential chemosensitivity in both the preclinical and clinical settings. The optimal chemotherapy regimen for this subset of patients still remains to be determined.

AB - BRCA mutation-associated breast cancers are characterized by deficient homologous recombination of DNA, and 80 % of BRCA1-associated breast cancers display the basal-like molecular subtype. Traditionally, BRCA carriers have received conventional systemic chemotherapy based on their baseline tumor characteristics, and it is generally accepted that after the appropriate treatment the prognosis of a mutation carrier is equivalent to that of a patient with sporadic breast cancer. However, with the growing understanding of the functions of BRCA1/2 proteins in homologous DNA repair, it is recognized that BRCA-associated breast cancer tumors may have distinct biochemical characteristics and thus require tailored treatment strategies. Tumors arising in patients with BRCA mutations were shown to be particularly sensitive to platinum compounds or inhibitors of poly(ADP-ribose) polymerase. In addition, BRCA1-mutation carriers seem to benefit from anthracycline-taxane-containing regimens as much as sporadic triple-negative breast cancers do. In this article, we review the functions of the BRCA1 and BRCA2 genes, and their differential chemosensitivity in both the preclinical and clinical settings. The optimal chemotherapy regimen for this subset of patients still remains to be determined.

KW - BRCA 1

KW - BRCA 2

KW - Chemotherapy

KW - Cisplatin

KW - PARP inhibitors

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84866532392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866532392&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2158-6

DO - 10.1007/s10549-012-2158-6

M3 - Article

C2 - 22791366

AN - SCOPUS:84866532392

VL - 135

SP - 355

EP - 366

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -